The finding that VEGF-B promotes retinal and choroidal NV and BRB breakdown suggests that VEGF-B may contribute to the complications of vasoproliferative ocular disorders and that it could be a therapeutic target for treating angiogenic ocular disorders and disorders leading to macular edema. This evidence concerns the gene VEGFB and macular retinal edema.